BETHESDA, Md., Feb. 12 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,today announced the publication of a comprehensive review article entitled,"BiTE: A new class of antibodies that recruit T cells" in the journal Drugs ofthe Future. BiTE(R) antibodies are designed to activate the body's T cells toseek and destroy cancer cells in a tightly controlled manner.
The review article discusses recently published preclinical and clinicaldata on BiTE antibodies, which are evolving into a new class of antibody-basedtherapeutics, with several new members in various stages of development. Oneemphasis is on CD19-specific BiTE antibody MT103 (also known as MEDI-538),which produced complete and partial responses at generally well tolerated andvery low doses in late-stage lymphoma patients. Another emphasis is on severalpreclinical studies showing significant anti-tumor activity of three otherBiTE antibodies targeting solid tumors by EpCAM (CD326), EphA2 or CEAantigens. All three tumor-associated antigens are found on many solid tumors.In addition, the article provides a detailed description of the mode of actionof BiTE antibodies, comparing it to natural T-cell responses.
"Our latest review article demonstrates the clinical progress and highlevel of scientific understanding the company has acquired in numerouspublished studies about its proprietary BiTE antibody technology," commentedPatrick A. Baeuerle, Micromet's chief scientific officer. "BiTE antibodiesrepresent a novel platform of clinically-validated, antibody-basedtherapeutics for the treatment of a wide range of cancers."
About BiTE(R) Antibodies
BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeuticapproach to cancer therapy. BiTE antibodies have been shown to induce animmunological synapse between a T cell and a tumor cell in the same manner asobserved during physiological T cell attacks. These cytolytic synapses enablethe delivery of cytotoxic proteins from T cells into tumor cells, ultimatelyinducing a self-destruction process in the tumor cell referred to as"apoptosis," or programmed cell death. In the presence of BiTE antibodies, Tcells have been demonstrated to serially eliminate tumor cells, which explainsthe activity of BiTE antibodies at very low concentrations and at very lowratios of T cells to target tumor cells. Through the process of killing cancercells, T cells proliferate, which leads to an increased number of T cells atthe site of attack.
Several antibodies in Micromet's product pipeline are BiTE antibodies andhave been generated based on Micromet's proprietary BiTE product developmentplatform. The most advanced BiTE antibody is MT103 (MEDI-538) targeting CD19,and is being tested in a phase 2 clinical trial in acute lymphoblasticleukaemia patients and in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting EpCAM(CD326), CEA and MCSP, are in pre-clinical development.
BiTE is a registered trademark of Micromet.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel,proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Three of its antibodies are in clinical development.MT103 (MEDI-538), the first antibody in Micromet's product pipeline developedutilizing the BiTE(R) antibody technology platform, is being evaluated in aphase 2 clinical trial for the treatment of patients with acute lymphoblasticleukemia, and in a phase 1 clinical trial for the treatment of patients withnon-Hodgkin's lymphoma. BiTE antibodies represent a new class of therapeuticantibodies that activate a patient's own cytot